There is no cure for COPD, but it can be managed and treated by working with your healthcare team to develop a plan to keep your COPD under control. Along with quitting smoking, staying up to date ...

causes mixed airway obstruction and restriction. A combination of both obstructive and restrictive breathing patterns may be seen when a person has more than one lung disease, such as cystic fibrosis ...

Though I attempted to follow my treatment plan and watched for signs of an impending exacerbation, one crept up on me this summer and caused a worsening of my dyspnea, or the shortness of breath that ...

This articles explores the causes, symptoms, diagnosis, and treatment of OCAD in more detail. It also discusses the potential outlook for people with OCAD and tips to help prevent the condition.

If you’ve been diagnosed with chronic obstructive pulmonary disease, or COPD, you probably have shortness of breath during physical exertion. Regular exercise may seem intimidating, but it’s ...

In most cases, bronchitis is not life-threatening. However, complications can arise, particularly in individuals with weakened immune systems, children, the elderly, or those with preexisting lung ...

With the earlier definition of chronic obstructive pulmonary disease (COPD), patients were ... and mucus plugging of the airways. Inflammation causes fibrosis in the airways and loss of tissue ...

1 Division of Pulmonary and Critical Care ... an inflammatory process and mucus plugging of the airways. Inflammation causes fibrosis in the airways and loss of tissue adjacent to it.

highlighting the heterogeneity in chronic inflammatory pathways that underlie chronic obstructive pulmonary disease (COPD) pathophysiology. In ‘A Breath of Fresh Air: A Greater Understanding of COPD ...

The main objective was to discuss the clinical aspects, diagnosis, and pathophysiology of bronchiectasis, a chronic, abnormal dilation of the bronchi, and its association with other lung diseases. The ...

The U.S. Food and Drug Administration has cleared the start of clinical trial testing of KT-621, Kymera Therapeutics’ oral therapy for chronic obstructive pulmonary disease (COPD) and other diseases ...